



Innovation Series 2024

November 14, 2024


10:30 AM – 2:15 PM ET

BIONTECH

1

Welcome & Introductory Remarks

Ryan Richardson,
Chief Strategy Officer



BIONTECH

This Slide Presentation Includes Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss), particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; BioNTech's acquisition of Biotheus, which is subject to customary closing conditions, including regulatory approvals; the impact of BioNTech's acquisition of Biotheus upon closing; collaboration and licensing agreements; the development, nature and feasibility of sustainable vaccine production and supply solutions; the deployment of AI across BioNTech's preclinical and clinical operations; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; and BioNTech's expectations of net profit / (loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this presentation are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations regarding its COVID-19 vaccine with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's and its counterparties' ability to manage and source necessary energy resources; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of COVID-19 on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market BioNTech's COVID-19 vaccine and, if approved, its product candidates; BioNTech's ability to manage its development and related expenses; regulatory developments in the United States and other countries; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended September 30, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise.

Innovation Series 2024 – Today's Presenters

Prof. Ugur Sahin, M.D.

Chief Executive Officer, Co-founder



Prof. Özlem Türeci, M.D.

Chief Medical Officer, Co-founder



Ryan Richardson

Chief Strategy Officer



Annemarie Hanekamp

Chief Commercial Officer




Prof. Ilhan Celik, M.D.

Vice President, Clinical Development



Michael Wenger, M.D.

Vice President, Clinical Development



Innovation Series 2024 Agenda


1	Welcome and Introductory Remarks	10:30 AM	10 min
2	The Next Frontiers in Oncology	10:40 AM	45 min
3	Commercialization: Next Era of BioNTech	11:25 AM	15 min
4	BNT327 ¹ Clinical Development Strategy	11:40 AM	45 min
	<i>Break</i>	12:25 PM	15 min
5	mRNA Cancer Vaccines	12:40 PM	30 min
6	Select Targeted Therapies: HER2-ADC BNT323/DB-1303 ² & CLDN6 CART BNT211	1:10 PM	25 min
7	Path to Value Creation	1:35 PM	5 min
8	Closing Remarks and Q&A	1:40 PM	30 min

BioNTech's Journey

2008

Founding & Platform Building

Seed financing & first collaborations



2019

Nasdaq IPO



2020-2022

COMIRNATY®¹ Development, approval & worldwide launch



From 2023

Advancing towards becoming a **multi-product biotechnology company**



BNT327/PM8002²



Autogene cevumeran³
FixVac



BNT211 (CAR-T)



BNT323/DB-1303⁴

Entering a new stage of value creation for patients, society and shareholders

Partnered with 1. Pfizer; 2. Biotheus; 3. Genentech, a member of the Roche Group; 4. DualityBio.

Driven to Address the World's Most Pressing Health Challenges

With pioneering technologies delivered at scale

COVID-19 VACCINE¹ GLOBAL LEADERSHIP >4.9 billion doses distributed >80 countries globally >50 % Comirnaty market share²			STRONG FINANCIAL POSITION € 17.8 bn total cash plus security investments³
MULTIPLATFORM ONCOLOGY PORTFOLIO 20 Clinical programs 13 Ongoing Phase 2 or 3 trials Genentech A Member of the Roche Group REGENERON Genmab BIOTHEUS DualityBio MediLink Therapeutics OncoC4		INFECTIOUS DISEASE PIPELINE 7 Clinical programs in high unmet need indications Partnership with Pfizer in respiratory and other high need indications Pfizer	
LEADER IN AI InstaDeep™		IN-HOUSE MANUFACTURING Bulk mRNA Individualized mRNA Modular mRNA Autologous Cell Therapy	

1. Partnered with Pfizer; 2. As of Q3 2024; 3. Consists of cash and cash equivalents of €9,624.6 million, non-current security investments of €1,137.2 million, and current security investments of €7,078.0 million, as of September 30, 2024.


Developing and Approving the First mRNA Medicine

The fastest vaccine development in the history of medicine¹

The strongest launch of any pharmaceutical product²

VACCINE INNOVATION

Most vaccines take years to develop, but scientists created multiple vaccines for SARS-CoV-2 within a year.



>4.9 billion doses of BNT162b2 shipped

>180 countries and territories³



1. Ball P. Nature. 2021; 2. Measured by sales recorded for a single product in a single year (>\$40 billion combined of direct sales recorded by Pfizer or BioNTech in both 2021 and 2022); 3. Cumulative doses shipped in the years 2021, 2022 and 2023.


Long-Term Need for Seasonally Adapted Vaccines Anticipated

Continuous evolution

Ongoing antigenic evolution of SARS-CoV-2^{1,2}

Long-term health consequences

Accumulating evidence demonstrates that COVID-19 vaccination reduces long-COVID⁴



Risk remains high


For severe COVID-19 in vulnerable populations³

Variant-adapted vaccines

Designed to be effective against multiple variants of concern⁵

1. World Health Organization Tracking SARS-CoV-2 variant www.who.int/en/activities/tracking-SARS-CoV-2-variants accessed 30 October 2023; 2. Global Initiative on Sharing All Influenza Data <https://gisaid.org/> accessed 30 October 2023; 3. FDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting June 15, 2023; 4 Brannock et al, Nature Comm. 2023; 5. Stankov M. V. et al., medRxiv pre-print, 5 October 2023.

COVID-19 and Influenza Disease Burdens Show Different Seasonality Patterns



COVID-19

- Hospitalization rates have been consistently and significantly above the level of influenza
- Epidemiology patterns do not perfectly overlap with influenza
- Market has been characterized by dual strain vaccine launches in two of the last three years

1. Respiratory Virus Hospitalization Surveillance Network; Data last updated: November 1, 2024; 2. <https://www.cdc.gov/flu/hcp/vaccine-supply/2023-2024.html>

Variant-Adapted Vaccine Approval Timelines Came Earlier as Compared to 2023

Approval dates of variant-adapted COVID-19 vaccines¹

	2023	2024	Approval Date Change
 US	Sep 11 (XBB.1.5)	Aug 22 (KP.2)	← 20 days
 EC	Sep 1 (XBB.1.5)	Jul 3 (JN.1)	← 60 days
 UK	Sep 5 (XBB.1.5)	Jul 24 (JN.1)	← 43 days
 JP	Sep 1 (XBB.1.5)	Aug 8 (JN.1)	← 24 days

Potential for further alignment of regulatory timelines and COVID-19 seasonal epidemiology to meet public health needs


1. Partnered with Pfizer;
JN.1 is a SARS-CoV-2 variant, KP.2 is a lineage of the JN.1 variant. KP.2 vaccine approval took place on September 26 and October 10 in the EU and UK, respectively.

COVID-19 Vaccine Franchise¹ with Lean Cost Structure

Key Business Features:

1. Global Market Leadership
2. Lean Fixed Cost Base Business
3. Potential for Cashflow Generation

2024 Financials up to 30 September (Q1-Q3)



1. Partnered with Pfizer.

Leveraging COVID-19 Vaccine Business Model for Sustainable Value Creation

Financial Strength



**Cash generative
COVID-19 vaccine
business¹**



Balance sheet

Innovative R&D Engine



Progressive Path Towards Value Creation



**Data updates
across pipeline**

2025



**First launches
in oncology**

2026 - 2028



**Multi-product
portfolio**

2030

1. Partnered with Pfizer.

Today's Focus: Key Value-Driving Oncology Programs

Transformational Opportunities with Pan Tumor Potential



BNT327/PM8002 (bispecific PD-L1xVEGF)¹



Autogene cevumeran² (personalized mRNA cancer vaccine)



FixVac (off-the-shelf TAA-targeting mRNA cancer vaccine)



BNT211 (CLDN6-targeted CAR-T + CLDN6 CAR-T amplifying vaccine)




BNT323/DB-1303 (HER2 ADC)³

Partnered with: 1. Biotheus; 2. Genentech, a member of the Roche Group; 3. DualityBio.

2

The Next Frontiers in Oncology

Prof. Ugur Sahin, M.D.
CEO and Co-founder



BIONTECH

Charting the Course for Tomorrow's Personalized Precision Medicine



Deep genomics & immunology expertise to analyze patient data




Individualized treatment platforms to address inter-individual variability




AI & digitally-integrated target & drug discovery and development



Automated in-house manufacturing to serve patients on time and globally




Our Concept Towards a Potentially Curative Approach to Cancer



This is a conceptual slide and does not imply published data as bases for.

Programs Currently Evaluated in Clinical Stage



Partnered with 1. DualityBio; 2. MediLink; 3. Biotheus; 4. Genentech, a member of the Roche Group; 5. Genmab; 6. OncoC4.

Select Candidates Suitable for Late-Stage Development Across Multiple Cancer Indications

Immunomodulators

BNT327/PM8002¹

PD-L1 × VEGF bispecific antibody

Validated across
25+ tumor types with >700
patients treated

Anti-VEGF A



Anti-PD-L1

- Broad applicability across range of cancers
- Planned Ph3 in SCLC, NSCLC and TNBC

mRNA Cancer Vaccines

BNT122 Autogene cevumeran²

Individualized Cancer Vaccine
Candidate

Personalized medicine targeting
patient-specific tumor antigens



- Targeting cancers in adjuvant stage
- Studies ongoing in CRC, PDAC, urothelial cancer and other solid tumors

Targeted Therapy

BNT211

Autologous CLDN6-targeting
CAR-T

±


CAR-T cell amplifying RNA
vaccine (“CARVac”)





- Targeting CLDN6+ cancers, including ovarian, testicular, endometrial, sarcoma, lung, and gastric cancer

BNT327/PM8002¹: Synergistic Targeting of PD-L1 and VEGF

BNT327/PM8002¹ characteristics: combined tumor targeting²



Selected NSCLC IHC³



Bispecific MOA


Targeting of PD-1 /PD-L1 blockade to VEGF high tumors

Targeting of VEGF neutralization to PD-L1 high tumors

1. Partnered with Biotheus; 2. Khan KA Nat Rev Clin Oncol 2018; 3. IHC data: Human Protein Atlas.

Anti-VEGF Treatment May Reverse Immune-Suppressive Effects and Potentially Improve Outcome of IO Treatment

VEGF signaling has **immunosuppressive** effects in addition to angiogenesis



Source: Khan KA Nat Rev Clin Oncol 2018; Marin-Acevedo JA and Hanna NH, ASCO 2023.

BNT327/PM8002¹ is Being Investigated Across Multiple Tumor Types with >700 Patients Treated

		Mono	Combo			Mono	Combo
Lung	1L NSCLC WT PD-L1+	✓		Breast	1L TNBC ★		+ Nab-Paclitaxel ✓
	2L+ NSCLC EGFRm	✓	+ Pemetrexed/Carboplatin ✓	Gastro-intestinal	1L HCC		+ FOLFOX4 ✓
	2L SCLC ★		+ Paclitaxel ✓		Advanced BTC	✓	
	1L SCLC ★		+ Etoposide/Platinum ✓	Genito-urinary	nccRCC	✓	
Gynaecology	PROC	✓			2L+ ccRCC	✓	
	2L+ PSOC	✓		Others	1L MPM		+ Pemetrexed / Platinum ✓
	2L+ Cervical Cancer	✓			2L NEN	✓	+ FOLFIRI ✓
	2L+ Endometrial Cancer	✓			1L Mucosal Melanoma	✓	

★ Data expected in Q4'2024-2025


✓ Ongoing studies with BNT327/PM8002

1. Partnered with Biotheus.

BNT327/PM8002¹ with nab-paclitaxel Shows Clinically Meaningful Efficacy Irrespective of PD-L1 Status in 1L TNBC

Phase 1/2b (NCT05918133): clinical activity of BNT327/PM8002¹ in combination with nab-paclitaxel
 Y. Meng et al. Presented at ESMO 2024. Presentation 384MO

Variable	ITT*	PD-L1 CPS<1	PD-L1 1≤CPS<10	PD-L1 CPS≥10
Population (n)	42	13	16	9
ORR %	73.8	76.9	56.3	100.0
DCR %	95.2	100.0	93.8	100.0
mPFS (mo)	13.5	NR	14.0	10.8



Benchmark comparator data by PD-L1 expression level

Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
TNBC (CPS <10)	Chemo	35%	5.6 mo	15.0 mo	KEYNOTE-355 ²
TNBC (CPS ≥10)	Pembro + Chemo	62%	9.7 mo	23.0 mo	KEYNOTE-355 ²

ITT population: mDoR 11.7 mos; mOS not reached

1. Partnered with Biotheus; 2. Cortes, J, et al. N. Engl. J. Med. 2022.
 *PD-L1 testing was not done in 4 patients (not shown). ORR: 75.0% and mPFS 14.0 months

BNT327/PM8002¹ May Drive Clinical Benefit Irrespective of PD-L1 Status


BNT327/PM8002¹ can potentially become backbone IO therapy **irrespective of PD-L1 status**

BNT327/PM8002¹ MOA

dual mechanisms: tumor targeting and synergy in reversing immunosuppression

Clinical signals observed

in studies enrolling >700 patients across 10+ Indications



BNT327/PM8002¹ + chemo in 1L TNBC

Y. Meng et al. Presented at ESMO 2024. Presentation 384MO



1. Partnered with Biotheus; Source: Y. Meng et al. Presented at ESMO 2024. Presentation 384MO.

Next-generation Bispecific Can Potentially Expand the Reach of IO Therapy

PD-(L)1 monotherapy approved in front line	PD-(L)1 approved as combination therapy or in later line	PD-(L)1 not currently approved
NSCLC PD-L1 $\geq 50\%$	NSCLC PD-L1 $<50\%$ ●	
	TNBC PD-L1 $\geq 10\%$	TNBC PD-L1 $<10\%$ ●
	SCLC	EGFRmut NSCLC ●
HNSCC PD-L1 $\geq 1\%$	HNSCC PD-L1 $<1\%$	HR+ HER2- BC
Melanoma	Endometrial Cancer ●	CRC (MSS) ●
MSI-H or dMMR solid tumors	Cervical Cancer ●	Glioblastoma ●
	HCC ●	Ovarian Cancer ●
	Gastric or GEJ Cancer PD-L1 $\geq 1\%$ ●	Gastric or GEJ Cancer PD-L1 $< 1\%$ ●
		PDAC

● Anti-VEGF approved indications

Only selected indications listed


Next-gen PD-(L)1xVEGF bispecific opportunity

Seek improved efficacy profile vs. existing IO

Explore indications non-responsive to current IO


Source: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli Label; Loqtorzi Label; Zynyz Label; Avastin Label; Cyramza Label; Lenvima Label; Votrient Label . Selected indications listed based on FDA approval.

Anti-PD-(L)1 Therapy Only Addresses a Fraction of Cancer Incidence




1. US incidence source: NIH and American Cancer Society data EU incidence source: European Cancer Information System, Indications listed on the previous slide are shown.

Significant Patient Population Not Addressed by Existing IO Therapies




1. US incidence source: NIH and American Cancer Society data EU incidence source: European Cancer Information System, Indications listed on the previous slide are shown.

We Aim to Bring New Approaches Across Indications through Our Combination Strategy



1. US incidence source: NIH and American Cancer Society data EU incidence source: European Cancer Information System, Indications listed on the previous slide are shown.


Focus on BNT327/PM8002¹ as Backbone for Late-Stage Development




1. Partnered with Biotheus; 2. Data on file.
Disclaimer: Conceptual schema, illustrative purpose only.

BNT327/PM8002¹ + BNT325/DB-1305² TROP2-ADC: Preclinical Data Demonstrate Enhanced Anti-Tumor Efficacy when Combined

Xenograft A375 PBMC-co injection model – A375 expressing TROP2 in B-NDG B2M



hTROP2-MC38 in wt mice



Partnered with: 1. Biotheus; 2. DualityBio.

BNT327/PM8002¹ Clinical Development

Taking Full Control of Global Rights and Clinical Programs

Global clinical trials	Indication	Target population	Regimen	Phase	Status
	SCLC	1L or 2L	+ chemo	2	Ongoing
	TNBC	1L or 2L	+ chemo	2	Ongoing
	SCLC	1L	+ chemo vs. atezolizumab + chemo	3	US IND approved
	NSCLC	1L	+ chemo vs. pembrolizumab + chemo	2/3	US IND approved
	TNBC	1L	+ chemo vs. chemo	3	Planned
	Selected solid tumors		+ BNT325/DB-1305 ²	1/2	Ongoing
	Selected solid tumors		+ BNT324/DB-1311 ²	1/2	US IND approved
	Selected solid tumors		+ BNT323/DB-1303 ²	1/2	US IND approved
China-based clinical trials	Indication	Target population	Regimen	Phase	Status
	TNBC	1L	+ chemo vs. chemo	3	Ongoing
	SCLC	2L	+ chemo vs. chemo	3	Ongoing
	NSCLC	2L+ EGFRmut	+ chemo	2/3	Ongoing
	SCLC	1L	+ chemo	2/3	Ongoing
		2L	+ chemo	2	Primary completion
	TNBC	1L	+ chemo	1/2	Ongoing
	HCC	1L	+ chemo	2	Ongoing
		1L	+ TIGIT x PVRIG (PM1009)	1/2	Ongoing
	NEN	2L	+ chemo	2	Ongoing
	MPM	1L	+ chemo	2	Ongoing
	Advanced solid tumors ³		mono	1/2	Primary completion

BNT327/PM8002
Proven capabilities of
BioNTech + Biotheus

>700 patients enrolled
across **10+** indications

19 clinical trials ongoing
or planned, including
3 global registrational
trials in 1L TNBC,
SCLC, and NSCLC

Partnered with: 1. Biotheus; 2. DualityBio; 3. Indications included in Ph2a: NSCLC, mucosal melanoma, renal cell carcinoma, endometrial cancer, cervical cancer, platinum resistant ovarian cancer.

Accelerating Global Clinical Development Program for BNT327/PM8002¹

Explore potential of BNT327/PM8002¹ in three waves of focused development

1 Establish

Ongoing

- Phase 2 in SCLC
- Phase 2 in TNBC

Planned

- Phase 2/3 NSCLC for 2024
- Phase 3 SCLC for 2024
- Phase 3 TNBC for 2025

2 Combine

Ongoing

- Phase 1/2 with BNT325/DB-1305² (TROP2) in solid tumors

Planned

- Phase 1/2 with BNT323/DB-1303² (HER2) in solid tumors for 2025
- Phase 1/2 with BNT324/DB-1311² (B7-H3) in solid tumors for 2025
- Additional combinations for 2025

BNT327/PM8002¹+ADC: Explore expansion to novel combinations with ADCs in high unmet need indications

3 Broaden

BNT327/PM8002¹ + novel:
Broaden to further indications

BNT327/PM8002¹+chemo: Establish in combination with chemotherapy in potential Fast-to-Market indications

Announced Planned Acquisition of Biotheus



BioNTech to Acquire Biotheus to Boost Oncology Strategy

November 13, 2024

- Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors
- With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations
- BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025
- BioNTech to pay \$800 million to acquire 100 percent of the issued share capital and up to \$150 million in potential milestone payments
- Additional details will be shared at BioNTech's Innovation Series R&D Day event on 14 November 2024

Upfront cash and BioNTech stock payment of **\$800 Million**

Milestone-based cash earn-out of **up to \$150 million**

Biotheus to become a **wholly-owned BioNTech subsidiary**

Closing expected **Q1 2025¹**

1. Subject to regulatory approvals and other customary closing conditions.

Biotheus Acquisition to Accelerate BNT327/PM8002¹ Development Execution

Anti-VEGF A



Anti-PD-L1 VHH

Advancing BNT327/PM8002¹ in multiple indications, aiming for first-to-market approvals



BNT327/ PM8002¹ development acceleration and expansion

Global control of BNT327/PM8002¹ development and commercialization program

Streamline execution of initial BNT327/PM8002¹ + ADC development plans




Clinical development capability establishment in China

~80-person clinical development organization in China with demonstrated execution ability



Manufacturing site supporting initial launch

cGMP manufacturing facility with multiple 2000L bioreactors



Full pipeline and platform ownership

Comprehensive E2E bispecific antibody discovery and development capabilities

6 clinical stage assets

Pre-clinical ADC pipeline

¹ Partnered with Biotheus.

Biotheus Manufacturing Facility to Supply Clinical Trial Expansion and Early Launches

Biotheus Brings Fully-Integrated CMC, Manufacturing and Fill Finish Capabilities

200L Pilot plant: support IND and Phase 1 studies

2000L Production plant:

Support global clinical development and early launches


IND documentation has met global regulatory standards including China, Australia and US



Biotheus 2000L cGMP manufacturing site

Oncology Treatment is Entering the Bispecific Antibody Era

IO therapies have relied on mAbs with a single target¹




TAA: tumor-associated antigen

1. Qin et al. Molecular Cancer (2019) 18:155. 2. Partnered with Biotheus.

Bispecific antibodies enable new opportunities

10 new bispecifics approved in the U.S. since 2021



Selected MoAs of novel bispecific antibodies



BNT327/PM8002² combines **tumor targeting** and **immune redirecting**

Biotheus' Fully-Integrated Antibody Discovery and Engineering Workflow

“Plug and Play” design enables screening of multiple formats for optimized lead selection

Selected antibody formats generated



2 Fabs + 2 VHHS



1 Fab + 1Fab




2 Fabs + 2 scFvs

24 months for BNT327/PM8002¹ from discovery to IND submission

9 clinical stage bispecifics generated

30+ preclinical bispecifics generated

Bispecific produced with a single cell line



Biotheus Pipeline Enables Exploration of Novel IO + IO Combinations

Biotheus Pipeline overview


Selected Clinical Assets

BNT327/PM8002 ¹ (PD-L1 × VEGF bispecific)	Phase 2 / Phase 3 in China
PM1009 (TIGIT × PVRIG bispecific)	Phase 1
PM1022 (TIGIT × PD-L1 bispecific)	Phase 1
PM1015 (CD73 mAb)	Phase 1
PM1080 ² (EGFR × cMET bispecific)	Phase 1
PM1032 (4-1BB × CLDN18.2 bispecific)	Phase 1

Multiple Pre-clinical Candidates

Multiple bispecifics in pre-clinical development, including bispecific ADCs.

A broad range of targets to be explored for IO+IO combos




1. Partnered with Biotheus; 2. Hansoh has been granted by Biotheus the exclusive rights to develop, commercialize and manufacture PM1080 in Greater China. Biotheus has ex-China rights.

3


Commercialization: Next Era of BioNTech

Annemarie Hanekamp,
Chief Commercial Officer



BIONTECH

BioNTech is in Transition to a Multi-Product Commercial Oncology Company



Partnered with: 1. Pfizer; 2. DualityBio; 3. Biotheus; 4. Genentech, a member of the Roche Group; Patient numbers sourced from DRG; LCM = Lifecycle Management.

Maintaining COVID-19 Vaccine Franchise¹ with Lean Commercial Infrastructure


Cash generating COVID-19 business structure

Maintained ~80% gross margin³

Low sales & marketing expenses

Shared R&D expenses

Lean commercial organization in Germany and Türkiye, leveraging partners' commercial infrastructures for global rollout of Comirnaty




1. Partnered with Pfizer; 2. Comirnaty is not approved in mainland China; 3. As of September 30, 2024

First Launch with BNT323/DB-1303¹ to Address Unmet Need in Endometrial and Breast Cancer Patients

Strategic launch to build-up BioNTech commercialization capabilities for future launches

Establish relationships with oncology community and payors

First step in building expertise in breast and gynecologic cancers



2030 projected incidence

1. Partnered with DualityBio; 2. Projected incidence using historical figures from American Cancer Society (US); Globocan (EU4+UK); 3. SEER; 4. Triangulation of Plotkin, et al., 2024, and Fleming, et al., 2009; 5. CancerMPact; 6. Modi et al., 2022; 7. Bergeron et al., 2023.


BNT327/PM8002¹: Combine with SoC Chemotherapy in Potential Fast-to-Market Indications

Building on existing commercial infrastructure, rapidly scaling up to establish lung and breast cancer franchises

Aiming to **address** remaining **high unmet need** through improved duration of response and survival

Expanding breast cancer franchise **while building a presence** in lung cancer

Establishing next-generation IO backbone for novel combinations



2030 projected incidence; * Final patient pool will depend on Ph3 design

1. Partnered with Biotheus; 2. Globocan – Cancer Tomorrow; 3. SEER data for diagnosed SCLC and TNBC incidence in US; 4. Cancer Research UK; 5. Zentrum für Krebsregisterdaten; 6. Sante Publique; 7. AIOM; 8. EPDATA

9. SEER Stat Research Tool; 10. CancerMPact 2024; 11. Dayen et al (2019); 12. Halpern et al (2007); 13. Devarakonda, et al., 2015; 14. Pikor, et al., 2013; 15. Lam, et al., 2019; 16. Friedlaender et al., 2019.

Creating an AI Infused Commercialization Model Focused on Delivering our Innovations to Patients at Scale




Launch

Build AI infused, optimized yet scalable commercial capabilities to launch BNT323/DB-1303¹



Establish

Leverage initial build to rapidly scale for BNT327/PM8002² and execute platform commercialization model



Expand

Future proof AI commercial model to deliver multiple innovations to address multiple patient populations

Aiming to Establish New Pillar of Care for Early-Stage Colorectal Cancer Patients with Autogene Cevumeran¹

Phased expansion into early-stage tumors with a novel platform modality

Percentage of **stage II high risk / stage III patients** who are expected to recur within 2-years of surgery⁷

65%
ctDNA+

CRC (2030)

US Incidence | **151K²**



Stage II (high) risk /
Stage III | **60K^{2,3}**



Adjuvant treated | **39K⁴**




MSI-L / MSS | **33K⁵**

ctDNA+ | 7K⁶


1. Partnered with Genentech, a member of the Roche Group; 2. Based on CancerMPact® Patient Metrics U.S., accessed in Feb 2024; 3. Babcock, B. et al. Ann. Surgical Onc., 2018; 4. Kotani D. et al. Nat Med, 2022; 5. Mulet-Margalef N. et al. Cancers, 2023; 6. Cohen, S.A. et al. Ann. Onc. 2022; 7. Nakamura Y. et al. Nat. Med., 2024.

Building a Patient-Centric Commercialization Model to Support the Establishment of Individualized mRNA Cancer Therapies

End-to-End capabilities orchestration required



BioNTech is in Transition to a Multi-Product Commercial Oncology Company



Partnered with: 1. Pfizer; 2. DualityBio; 3. Biotheus; 4. Genentech, a member of the Roche Group; Patient numbers sourced from DRG; LCM = Lifecycle Management.

4

BNT327 Clinical Development Strategy

Prof. Ilhan Celik, M.D.
VP Clinical Development



BIONTECH

Accelerating Global Clinical Development Program for BNT327/PM8002¹

Explore potential of BNT327/PM8002¹ in three waves of focused development

1 Establish

Ongoing

- Phase 2 in SCLC
- Phase 2 in TNBC

Planned

- Phase 2/3 NSCLC for 2024
- Phase 3 SCLC for 2024
- Phase 3 TNBC for 2025

2 Combine

Ongoing

- Phase 1/2 with BNT325/DB-1305² (TROP2) in solid tumors

Planned

- Phase 1/2 with BNT323/DB-1303² (HER2) in solid tumors for 2025
- Phase 1/2 with BNT324/DB-1311² (B7-H3) in solid tumors for 2025
- Additional combinations for 2025

BNT327/PM8002¹+ADC: Explore expansion to novel combinations with ADCs in high unmet need indications

3 Broaden

BNT327/PM8002¹ + novel:
Broaden to further indications

BNT327/PM8002¹+chemo: Establish in combination with chemotherapy in potential Fast-to-Market indications

Next-generation Bispecific Can Potentially Expand the Reach of IO Therapy

PD-(L)1 monotherapy approved in front line	PD-(L)1 approved as combination therapy or in later line	PD-(L)1 not currently approved
NSCLC PD-L1 $\geq$ 50%	NSCLC PD-L1 <50% ●	
	TNBC PD-L1 $\geq$ 10%	TNBC PD-L1 <10% ●
	SCLC	EGFRmut NSCLC ●
HNSCC PD-L1 $\geq$ 1%	HNSCC PD-L1 <1%	HR+ HER2- BC
Melanoma	Endometrial Cancer ●	CRC (MSS) ●
MSI-H or dMMR solid tumors	Cervical Cancer ●	Glioblastoma ●
	HCC ●	Ovarian Cancer ●
	Gastric or GEJ Cancer PD-L1 $\geq$ 1% ●	Gastric or GEJ Cancer PD-L1 < 1% ●
		PDAC

● Anti-VEGF approved indications

Only selected indications listed


Next-gen PD-(L)1xVEGF bispecific opportunity

Seek improved efficacy profile vs. existing IO

Explore indications non-responsive to current IO

Source: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli Label; Loqtorzi Label; Zynyz Label; Avastin Label; Cyramza Label; Lenvima Label; Votrient Label . Selected indications listed based on FDA approval.

TNBC Patients Face Poor Outcomes Due to Limited Therapeutic Options



1.Incidence from SEER (US); Zentrum für Krebsregisterdaten (DE); Globocan (ES); Sante Publique (FR); AIOM (IT); Cancer Research UK 2. CancerMPact® 2024 Treatment Architecture EU5 and US 3.Danziger N, et al. , Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. Oncologist. 2023 Apr 6;28(4):319-326. 4. Cortes, J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 387, 217–226.

BNT327/PM8002¹ in Combination with Nab-Paclitaxel for 1L Metastatic TNBC

Phase 1b/2 (NCT05918133)

Y. Meng et al. Presented at ESMO 2024. Presentation 384MO

Key inclusion criteria

- Age 18-75 years with life expectancy ≥ 12 weeks
- Histologically or cytologically confirmed unresectable adv. or met. ER, PR, HER-2 negative TNBC
- No prior systemic therapy despite taxane in (neo)adj. settings, ≥ 12 months
- ≥ 1 measurable lesion (RECIST 1.1)
- ECOG PS 0-1
- Adequate organ function

n=60

BNT327/PM8002¹ + Nab-paclitaxel

Treatment continued until
Disease progression
or
Unacceptable toxicity



Key endpoints

Primary endpoints: ORR per RECIST1.1, safety (NCI-CTCAE v5.0)

Secondary endpoints: PFS, DCR, OS

Benchmark comparator data for 1L TNBC by PD-L1 expression level

Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
TNBC (CPS <10)	Chemo	35%	5.6 mo	15.0 mo	KEYNOTE-355 ^{2,3}
TNBC (CPS ≥ 10)	Pembro + Chemo	62%	9.7 mo	23.0 mo	KEYNOTE-355 ²

1. Partnered with Biotheus; 2. J. Cortes et al, Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer, N. Engl. J. Med. 387 (2020) pp 217-226; 3. Obtained from subgroup analysis.

BNT327/PM8002¹: Safety Profile Appears Manageable in 1L TNBC

Phase 1b/2 (NCT05918133) Y. Meng et al. Presented at ESMO 2024. Presentation 384MO			
Safety Overview (N=42)		TRAEs of Interest (N=42)	
	n (%)	All grades, n (%)	Grade ≥ 3, n (%)
All TRAEs	42 (100)	Neutrophil count decreased	36 (85.7) 13 (31.0)
Grade ≥3 TRAEs	24 (57.1)	White blood cell count decreased	32 (76.2) 10 (23.8)
SAEs	10 (23.8)	Anaemia	32 (76.2) 2 (4.8)
TRAE leading to dose interruption	27 (64.3)	Proteinuria	24 (57.1) 2 (4.8)
TRAE leading to dose reduction	7 (16.7)	Hypertriglyceridaemia	18 (42.9) 4 (9.5)
TRAEs leading to treatment discontinuation	2 (4.8)	Epistaxis	17 (40.5) 0
irAE	15 (35.7)	Aspartate aminotransferase increased	11 (26.2) 2 (4.8)
Grade ≥3 irAE	4 (9.5)	Alanine aminotransferase increased	10 (23.8) 1 (2.4)
		Hypertension	8 (19.0) 2 (4.8)

Observed TRAEs are known safety signals of PD-(L)1 / VEGF-A targeting therapies plus chemotherapy and resulted in low discontinuation rate

1. Partnered with Biotheus.

BNT327/PM8002¹ in Combination with Chemo Shows Clinically Meaningful Efficacy in 1L TNBC Irrespective of PD-L1 Status


Phase 1/2b (NCT05918133):
Y. Meng et al. Presented at ESMO 2024. Presentation 384MO

Data update at SABCS
December 11, 2024

Variable	ITT*	PD-L1 CPS<1	PD-L1 1≤CPS<10	PD-L1 CPS≥10
Population (n)	42	13	16	9
ORR % (95% CI)	78.6 (63.2, 89.7)	76.9 (46.2, 95.0)	68.8 (41.3, 89.0)	100.0 (66.4, 100.0)
cORR % (95% CI)	73.8 (58.0, 86.1)	76.9 (46.2, 95.0)	56.3 (29.9, 80.3)	100.0 (66.4, 100.0)
DCR % (95% CI)	95.2 (83.8, 99.4)	100.0 (75.3, 100.0)	93.8 (69.8, 99.8)	100.0 (66.4, 100.0)

mPFS (Mo), (95%CI)	13.5 (9.4, --)	NR (5.7, --)	14.0 (7.2, --)	10.8 (5.5, 13.5)
-----------------------	-------------------	-----------------	-------------------	---------------------

For the ITT population, mDoR 11.7 mos; mOS was not reached




Benchmark comparator data for 1L TNBC by PD-L1 expression level					
Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
TNBC (CPS <10)	Chemo	35%	5.6 mo	15.0 mo	KEYNOTE-355 ²
TNBC (CPS ≥10)	Pembro + Chemo	62%	9.7 mo	23.0 mo	KEYNOTE-355 ²

1. Partnered with Biotheus; 2. Cortes, J, et al. N. Engl. J. Med. 2022. SABCS = San Antonio Breast Cancer Symposium.
*PD-L1 testing was not done in 4 patients (not shown). ORR: 75.0% and mPFS 14.0 months.

BNT327/PM8002¹ Phase 2 in Combination with Chemotherapy for 1L/2L Triple Negative Breast Cancer

BNT327-02 (NCT06449222)



Key endpoints

Primary endpoints: ORR per RECIST v1.1 and safety according to NCI-CTCAE v5.0

Benchmark comparator data for 1L TNBC by PD-L1 expression level					
Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
TNBC (CPS <10)	Chemo	35%	5.6 mo	15.0 mo	KEYNOTE-355 ²
TNBC (CPS ≥10)	Pembro + Chemo	62%	9.7 mo	23.0 mo	KEYNOTE-355 ²

Phase 3 trial planned for 2025


BNT327/PM8002¹ in Combination with Chemotherapy for EGFR-mutated, post-TKI NSCLC

Phase 2 study of BNT327/PM8002¹ + carbo/pem in EGFRm NSCLC post EGFR TKI (NCT05756972)

Adapted from Wu YL et al. Presented at ESMO 2024. Mini oral 1255MO.

Inclusion criteria

- Age ≥ 18 years
- Nonsquamous Stage IIIB/C and IV NSCLC ineligible for surgery or local therapy
- EGFR sensitizing mutation
- Failure of EGFR-TKI treatment(s)
- No other prior systemic therapy than EGFR-TKIs
- Asymptomatic/stable brain metastasis allowed



Key endpoints

Primary endpoint: ORR per RECIST v1.1

Benchmark comparator data for 2L+ EGFR-mutated NSCLC

Status	Benchmark regimen	ORR	mPFS	mOS	Benchmark study
Current SoC	Chemo	29.0%	4.2mo	15.3mo	MARIPOSA-2 ²
Recent Approval	Amivantamab + chemo	53.0%	6.3mo	17.7mo	MARIPOSA-2 ²

1. Partnered with Biotheus; 2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf (accessed on 13Nov2024)

Safety Profile of BNT327/PM8002¹ + Chemotherapy in Patients with EGFRm NSCLC after Progressing on Prior EGFR TKI

Phase 2 study of BNT327/PM8002¹ + carbo/pem in EGFRm NSCLC post EGFR TKI (NCT05756972)
 Adapted from Wu YL et al. Presented at ESMO 2024. Mini oral 1255MO.

Safety Overview, TRAE, (n=64)		n (%)	TRAEs of Interest (N=64)		All grades, n (%)	Grade ≥ 3, n (%)
Any		63 (98.4)	White blood cell count decreased		48 (75.0)	9 (14.1)
Grade ≥3		39 (60.9)	Anaemia		47 (73.4)	6 (9.4)
SAE		11 (17.2)	Neutrophil count decreased		44 (68.8)	19 (29.7)
Leading to interruption of BNT327/PM8002		20 (31.3)	Platelet count decreased		37 (57.8)	6 (9.4)
Leading to discontinuation of	only BNT327/PM8002	4 (6.3)	Alanine aminotransferase increased		34 (53.1)	1 (1.6)
	only chemotherapy	4 (6.3)	Aspartate aminotransferase increased		31 (48.4)	1 (1.6)
	BNT327/PM8002 and chemotherapy	1 (1.6)	Proteinuria		25 (39.1)	1 (1.6)
Leading to death*		1 (1.6)	Gamma-glutamyltransferase increased		24 (37.5)	5 (7.8)
Any-grade immune-related		26 (40.6)	Lymphocyte count decreased		24 (37.5)	7 (10.9)
Grade ≥3 immune-related		4 (6.3)	Hypertension		13 (20.3)	5 (7.8)
Grade ≥3 VEGF-related (hypertension/elevated blood pressure, proteinuria, epistaxis, hemoptysis)		7 (10.9)				


Observed TRAEs are known safety signals of PD-(L)1 / VEGF-A targeting therapies plus chemotherapy and resulted in low discontinuation rate

1. Partnered with Biotheus; *TRAE leading to death: 1 case of pneumonia.

BNT327/PM8002¹ in Combination with Chemo Shows Clinically Meaningful Efficacy in EGFRm NSCLC Irrespective of PD-L1 Status

Phase 2 study of BNT327/PM8002¹ + carbo/pem in EGFRm NSCLC post EGFR TKI (NCT05756972)

Adapted from Wu YL et al. Presented at ESMO 2024. Mini oral 1255MO.




1. Partnered with Biotheus;
PD = progressive disease; PD-L1 = programmed cell death ligand 1; PR = partial response; SD = stable disease.

Non-Small Cell Lung Cancer is One of the Highest Incidence Cancers Globally¹

2030 U.S., EU4, U.K.
NSCLC incidence¹

~415k




Treatment outcomes vary based on histology and PD-L1 levels in 1L NSCLC patients without actionable genomic alterations

	Non-squamous (~ 70%) ³	Squamous (~ 30%) ³
PD-L1 ≥ 50% (~ 25 - 30%) ^{4,5}	5-year OS: 30% (KN-189) ⁶	5-year OS: 23% (KN-407) ⁷
PD-L1 1 - 49% (~ 30 - 40%) ^{4,5}	5-year OS: 20% (KN-189) ⁶	5-year OS: 21% (KN-407) ⁷
PD-L1 < 1% (~ 30 - 40%) ^{4,5}	5-year OS: 10% (KN-189) ⁶	5-year OS: 11% (KN-407) ⁷

1. Globocan – Cancer Tomorrow. 2. CancerMPact® 2024 Treatment Architecture EU5 and US; Note that 5-year survival reported includes all comor NSCLC population ie including with actionable genetic alterations. 3. Ganti AK, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021 Dec; 4. Mansour MSI et al PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. Int J Mol Sci. 2022 Apr 19;23(9):4517; 5. Saez de Gordo, K. et al. PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. Diagnostics 2021, 11, 1452; 6. Garassino MC, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41(11):1992-1998; 7. Silvia Novello et al., Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. JCO 41, 1999-2006(2023).

BNT327/PM8002¹: Phase 1/2 Dose Expansion Trial with Monotherapy in 1L NSCLC



BNT327/PM8002¹: Monotherapy Safety Profile Appeared Manageable in 1L NSCLC

Phase 1b/2a (NCT05918445): Safety across all 3 NSCLC cohorts
Wu, C. et al. presented at ASCO 2024. Poster #8533.

Safety overview (n=61)	n (%)	Common TRAEs (n=61)	All grades, n (%)	Grade ≥ 3, n (%)
All TRAEs	52 (85.2)	Proteinuria	33 (54.1)	3 (4.9)
TRAE ≥3	12 (19.7)	Hypertension	15 (24.6)	6 (9.8)
irAEs	24 (39.3)	Hypothyroidism	13 (21.3)	0
SAE	15 (24.6)	Hypoalbuminemia	12 (19.7)	0
TRAE leading to dose discontinuation	5 (8.2)	Hypocalcemia	11 (18.0)	0
		Anemia	9 (14.8)	1 (1.6)
		Alanine aminotransferase increased	8 (13.1)	8 (13.1)

No Grade 4/5 TRAEs observed, most AEs were Grades 1-2


1. Partnered with Biotheus.

BNT327/PM8002¹ Monotherapy Efficacy in 1L NSCLC

Phase 1b/2a (NCT05918445): cohort 1, 1L NSCLC (EGFR & ALK WT)
Wu, C. et al. presented at ASCO 2024. Poster #8533.

Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
1L NSCLC (PD-L1 ≥ 50%)	Pembro monotherapy	45%	7.7 mo	26.3 mo	KEYNOTE-024 ²

Waterfall/spider plots and Kaplan-Meier curves (PFS)



1L NSCLC mono tx (cohort 1, n=17): ORR 47%, DCR 100%, mPFS 13.6 months
Comparable ORR in PD-L1 1–49% (n=9) and PD-L1 ≥ 50% (n=8)

Phase 2/3 to initiate by YE 2024


1. Partnered with Biotheus; 2. Reck, M. et al. NEJM 2016.

Extensive-Stage Small Cell Lung Cancer is a High-Incidence Cancer with Poor Long-term Survival Rates

2030 U.S., EU4, U.K.
SCLC incidence¹

~60k

SCLC Staging distribution²



High unmet need for ES-SCLC patients as long-term survival outcomes remain very poor

	Limited-Stage SCLC	Extensive-Stage SCLC
mOS	CRT: 25 – 30 mos (CONVERT) ³	Atezo + chemo: 12.3 mos (IMPower133) ^{4,5}
24 mos OS	CRT: ~ 50% (CONVERT) ³	Atezo + chemo: ~ 25% (IMPower133) ^{4,5}
5-year survival ²	20%	3%

1.Incidence from: SEER data for diagnosed SCLC incidence in US; Cancer Research UK; Zentrum für Krebsregisterdaten; Sante Publique; AIOM; EPDATA.

2.Statistics from Dayen et al (2019); CancerMPact® Patient Metrics US & EU5, accessed February 2024. *Due to limited survival data in EU5, U.S. survival data is reported;

3.Walls, Gerard M. et al.Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT TrialInternational Journal of Radiation Oncology, Biology, Physics, Volume 119, Issue 5, 1386 - 1390

4.L. Horn et al, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancerN. Engl. J. Med., 379 (2018), pp. 2220-2229

5.Stephen V. Liu et al., Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). JCO 39, 619-630(2021).


BNT327/PM8002¹ in Combination with Paclitaxel for 2L SCLC

Phase 2 (NCT05879068)

Key Inclusion criteria

Patients with advanced SCLC who progressed after platinum-based chemotherapy with or without checkpoint inhibitors

- Age ≥ 18 years
- ECOG PS 0-1



Key endpoints

Primary endpoints: ORR per RECIST1.1, TRAEs incidence and severity

Secondary endpoints: DCR, DoR, PFS and OS

Benchmark comparator data for 2L+ SCLC

Status	Benchmark regimen	ORR	mPFS	mOS	Benchmark study
Current SoC	Chemo	29%	4.0 mo	7.6 mo	ATLANTIS ²
Recent Approval	tarlatamab	40%	4.9 mo	14.3 mo	DeLLphi-301 ³

1. Partnered with Biotheus 2. Aix S.P. et al. Lancet Resp Med 2023. 3. Ahn M. et al. NEJM 2023.

BNT327/PM8002¹ Combined with Paclitaxel Shows Acceptable Safety Profile in 2L SCLC

Phase 2 (NCT05879068) Ying Cheng et al. Presented at ESMO 2023. Poster#1992P				
Safety overview (n=48)		n (%)	TRAE ≥10% of patients	All grades, n (%) Grade ≥ 3, n (%)
All TRAEs		45 (93.8)	Neutropenia	23 (47.9) 22 (45.9)
TRAE ≥3		30 (62.5)	Leukopenia	23 (47.9) 12 (25.0)
SAE		16 (33.3)	Decreased platelet count	12 (25.0) 1 (2.1)
TRAE leading to treatment discontinuation		1 (2.1)	Anemia	11 (22.9) 0
			Proteinuria	9 (18.8) 2 (4.2)
			Pneumonitis	6 (12.5) 1 (2.1)*
*One grade 5 event due to pneumonitis				



Observed TRAEs are known safety signals of PD-(L)1 / VEGF-A targeting therapies plus chemotherapy and resulted in low discontinuation rate (2.1%)

1. Partnered with Biotheus.

BNT327/PM8002¹ Combined with Paclitaxel Shows Efficacy in 2L SCLC

Phase 2 (NCT05879068)

Ying Cheng et al. Presented at ESMO 2023. Poster#1992P



ORR for current SoC therapies in 2L+ SCLC ranges from 24-40% ²


1. Partnered with Biotheus; 2. On-label ORR for topotecan (24%), lurbinectin (35%), and tarlatamab (40%).

BNT327/PM8002¹: Phase 2 Dose Optimization in Combination with Chemotherapy for 1L/2L SCLC

BNT327-01 (NCT06449209)

Key Inclusion criteria

- Cohort 1: Untreated ES-SCLC or LS-SCLC with TFI≤6 months since last treatment
- Cohort 2 & 3: SCLC with disease progression after 1L platinum based CTx (w/wo IO) or 2L CTx



- **Three cohorts** based on previous treatment for patients and chemo option used to combine with BNT327/PM8002¹
- Each cohort randomized to receive two different dose levels BNT327/PM8002¹ with chemo



Key endpoints

Primary endpoints: ORR per RECIST v1.1 and safety according to NCI-CTCAE v5.0
Secondary endpoints: DoR, DCR, PFS per RECIST v1.1 and OS

Benchmark comparator data for 1L ES-SCLC

Benchmark regimen	ORR	mPFS	mOS	Benchmark study
Atezo + chemo	60%	5.2 mo	12.3 mo	IMPower133 ²

Phase 3 to initiate by YE 2024

1. Partnered with Biotheus; 2. L. Horn et al, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancerN. Engl. J. Med., 379 (2018), pp. 2220-2229.

Accelerating Global Clinical Development Program for BNT327/PM8002¹

Explore potential of BNT327/PM8002¹ in three waves of focused development

1 Establish

Ongoing

- Phase 2 in SCLC
- Phase 2 in TNBC

Planned

- Phase 2/3 NSCLC for 2024
- Phase 3 SCLC for 2024
- Phase 3 TNBC for 2025

2 Combine

Ongoing

- Phase 1/2 with BNT325/DB-1305² (TROP2) in solid tumors

Planned

- Phase 1/2 with BNT323/DB-1303² (HER2) in solid tumors for 2025
- Phase 1/2 with BNT324/DB-1311² (B7-H3) in solid tumors for 2025
- Additional combinations for 2025



BNT327/PM8002¹+ADC: Explore expansion to novel combinations with ADCs in high unmet need indications

3 Broaden

BNT327/PM8002¹ + novel:
Broaden to further indications

BNT327/PM8002¹+chemo: Establish in combination with chemotherapy in potential Fast-to-Market indications

Well-Positioned in ADCs with Therapeutic Candidates Across Multiple Tumors

BNT323/DB-1303 ¹	BNT324/DB-1311 ¹	BNT325/DB-1305 ¹	BNT326/YL202 ²
			
Targeting HER2 , cleavable linker and topoisomerase I inhibitor DAR: 8	Targeting B7H3 , cleavable linker and topoisomerase I inhibitor DAR: 6	Targeting TROP2 , cleavable linker and topoisomerase I inhibitor DAR: 4	Targeting HER3 , cleavable linker allows for intracellular and extracellular release of topoisomerase I inhibitor DAR: 8
Clinical status - Ph3 in HR+HER2-low mBC - Ph1/2 in multiple solid tumors	Clinical status Ph1/2 in multiple solid tumors	Clinical status Ph1/2 in multiple solid tumors	Clinical status Ph1 in multiple solid tumors

Expression level by indication³


High
Medium / Low
Very low / None

Target	NSCLC	SCLC	HER2+ BC	HR+ BC	TNBC	CRC	Gastric	Ovarian	PDAC	HNSCC	Prostate	Other high expression indications
HER2												Gynecologic
TROP2												
B7H3												UC, EC
HER3												

Partnered with: 1. DualityBio; 2. MediLink;
3. RNAseq data from AACR Project GENIE.

BNT327/PM8002 + ADC Combinations are Planned or Ongoing

Combination with
BNT325/DB-1305
is ongoing and
additional
combinations are
planned





Time for a
15 minute
break

5

mRNA Cancer Vaccines


Prof. Özlem Türeci, M.D.
CMO and Co-founder

Michael Wenger, M.D.
VP, Clinical Development


BIONTECH

Uridine-based mRNA-LPX Vaccines for Systemic Delivery and Induction of Potent Polyspecific Immune Responses Against Cancer Antigens


Uridine-based RNA in formulated LPX (RNA-LPX) and administered IV for preferential delivery to the APCs in spleen, lymph nodes and bone marrow




RNA-LPX is optimized for immune response stimulation



RNA-LPX combines targeted antigen delivery with stimulation of TLR-mediated IFNα immune response




Secretory signal peptide
for translocation of the nascent polypeptide chain into the endoplasmic reticulum



MITD (MHC class I trafficking domain)

5' cap, UTRs, poly(A) tail engineered for optimized stability and translational performance
Uridine chemistry for intrinsic adjuvanticity

Full Exploitation of Cancer Vaccine Target Space



1. In collaboration with Genentech, a member of the Roche Group. * Antigens vary across programs; ** T cell responses analyzed by ex vivo multimer staining analysis in blood.

Multiple Clinical Trials Demonstrate Execution Across iNeST and FixVac Portfolio

Individualized vaccine: iNeST					FixVac		
Autogene cevumeran (BNT122/RO7198457) ¹					BNT111 ²	BNT113	BNT116
Adjuvant		1L		R/R	R/R	1L	Multiple settings
MIUC Phase 2 + Nivolumab	CRC Phase 2 Monotherapy	PDAC Phase 2 + Atezolizumab	Melanoma Phase 2 + Pembrolizumab	Solid Tumors Phase 1 + Atezolizumab	Melanoma Phase 2 + Cemiplimab	HPV16+ HNSCC Phase 2 + Pembrolizumab	NSCLC Phase 1 & 2 Monotherapy, + Cemiplimab or CTx
Recruitment started	Recruitment ongoing Data presented from epi sub-study at ASCO 2024 and from biomarker sub-study at ESMO-GI 2024 .	Recruitment ongoing Data presented from investigator-initiated Ph 1 trial at ASCO 2022 & AACR 2024 and published. (Rojas et al., Nature 2023)	Enrollment completed Ph 1 data on prototype vaccine published (Sahin et al., Nature 2017). Analysis of Ph 2 PFS as primary endpoint will be based on events and defined when reporting results.	Enrollment completed Data presented at AACR 2020. Manuscript accepted in Nature Medicine	Enrollment completed Positive topline data announced July 2024 Data presented from Ph 1 at multiple conferences incl. SITC 2021 and published. (Sahin et al., Nature 2020)	Recruitment ongoing Ph 2 data presented at multiple conferences incl. ESMO-IO 2022 Data from safety run-in of Ph 2 trial and Ph1/2 IIT presented at ESMO 2024 .	Recruitment ongoing in Ph 2 in 1L NSCLC ² Ph 1 trial ongoing. Data presented at SITC 2023, AACR 2024 , and SITC 2024 .


1. Partnered with Genentech, a member of the Roche Group; 2. In collaboration with Regeneron.

Evaluating Autogene Cevumeran¹ in the Adjuvant Treatment Setting for Cancers of High Unmet Need

Rationale for adjuvant setting

Low tumor mass with residual cancer cells

Resistance mechanisms and immune suppression not fully established



Healthier immune system and uncompromised T-cell function

Unmet medical need

Pancreatic Ductal Adenocarcinoma

69–75% relapse rate within 5 years after adjuvant therapy^{2,3}

- Projected to be **2nd leading cause of cancer-related death** (US) by 2030⁴
- **5-year survival rates** after resection are **~10%**⁵
- Largely **CPI resistant** due to low mutation burden ⁶

Phase 1 trial completed and published
Randomized Phase 2 trial ongoing

Colorectal Cancer

20-35% relapse rate within 4 years after adjuvant therapy⁷



- **5-year survival** rates of locoregional disease are **~70%**⁸
- Median **disease-free survival** for **ctDNA-positive**, Stage 2 (high risk) and Stage 3 CRC post adjuvant chemotherapy: **~ 11 months** (**Reinacher-Schick et al., ASCO 2024**)

Randomized Phase 2 trial ongoing
Data update in late 2025 / early 2026

1. Partnered with Genentech, a member of the Roche Group; 2. Jones et al., JAMA Surgery 2019; 3. Conroy et al., JAMA Oncology 2022; 4. Rahib et al., JAMA Network Open 2021; 5. Bengtsson et al., Sci Rep 2020; 6. Kabacaoglu et al., Frontiers Immunol 2018; 7. André et al., JCO 2015; 8. NIH SEER cancer stat facts (Accessed October 30, 2024).

Response to Autogene Cevumeran¹ Correlates with Delayed PDAC Recurrence

Phase 1, investigator-initiated trial in resectable PDAC: 3-year follow-up data
Balachandran et al., AACR 2024. #CT025 & Rojas et al., Nature 2023.



At risk			Years		
Responder	8	8	7	5	0
Non-responder	8	5	1	1	0

Half of all patients mounted neoantigen-specific *de novo* T cell responses against at least one vaccine neoantigen

1. Partnered with Genentech, a member of the Roche Group.

Autogene Cevumeran¹ Investigated in a Phase 2 Randomized Trial vs SoC in Resected PDAC Patients

IMCODE003: Phase 2, open-label, multicenter, randomized trial (NCT05968326)

Key inclusion criteria

- Patients with resected PDAC
- No prior systemic anti-cancer treatment for PDAC
- No evidence of disease after surgery

Randomization

6-12 weeks after surgery

Screening Part A

Determine ≥ 5 neo-epitopes from blood and tumor samples for custom manufacture of autogene cevumeran

Screening Part B

Confirm patient eligibility

n=260
R 1:1

Treatment phases and dosing schedules

Patients are monitored at scheduled intervals until PDAC recurrence, occurrence of new cancers, or unacceptable toxicity.

Autogene cevumeran¹ + atezolizumab + mFOLFIRINOX

mFOLFIRINOX

Benchmark comparator data

Indication	Benchmark regimen	mDFS	mOS	5yr DFS	5yr OS	Benchmark study
Adjuvant PDAC	mFOLFIRINOX	21.4mo	53.5mo	26.1%	43.2%	PRODIGE 24 ²



Key endpoints

Primary: DFS

Secondary: DFS rates, OS, OS rates and safety




Status

- Recruitment ongoing

1. Partnered with Genentech, a member of the Roche Group; 2. Conroy et al., JAMA Onc. 2022.

Post-Surgery ctDNA Positivity in CRC is Associated with Significantly Shorter DFS and Can Identify Patients at High Risk of Disease Recurrence

BNT000-001: A Multi-Site Epidemiological Study of ctDNA Status in Stage II/III CRC Patients After Resection and Prior to Adjuvant Chemotherapy (NCT04813627)
Reinacker-Schick. et al., ASCO 2024. Abstract #3526.



ctDNA-	741	489	402	295	187	120	64	30	6	1	0
ctDNA+	55	33	22	15	8	4	2	1	0		

DFS rates at 12 and 18 months¹

	ctDNA- (n=741)	ctDNA+ (n=55)*
Events, n (%)	31 (4.2)	20 (36.4)
Median DFS (IQR), months	Not reached (24.6, NR)	10.55 (7.2, 14.4)
12-month DFS rate (95% CI), %	93.2 (90.3, 96.2)	47.2 (31.9, 69.8)
18-month DFS rate (95% CI), %	84.9 (79.1, 91.2)	23.6 (10.6, 52.3)

1. Data cut off: 15 March 2024. Patients who transferred to BNT122-01 (n=56) were excluded from this analysis.

Autogene Cevumeran¹ Investigated in a Phase 2 Randomized Trial vs. Watchful Waiting in Adjuvant Colorectal Cancer

BNT122-01: Phase 2, multi-site, open-label, randomized, controlled trial (NCT04486378)

Key inclusion criteria

- Patients with surgically-resected Stage II (high-risk) or Stage III CRC

Adjuvant SoC chemotherapy for 12–24 weeks

Screening 1

ctDNA status (post-operative)

Screening 2

neoantigen selection for vaccine manufacture

Screening 3

final eligibility (ctDNA+ patients only)

Biomarker: Autogene cevumeran¹

irrespective of ctDNA status (n=15)

iNeST manufacturing

≤20 neoepitopes



Exploratory: Autogene cevumeran¹

recurrent disease at Screening 3 (n≤20)

n=164
R 1:1

Autogene cevumeran¹

15 doses: 6×Q1W, 2×Q2W, 7×Q6W

Observational watchful waiting



Key endpoints

Primary: Disease-free survival

Efficacy: RFS, TTR, TTF, OS

Change in ctDNA status

Historical efficacy in CRC patients^{2, 3}

mDFS in ctDNA+ patients: 6 months

5-year DFS rate: stage II (high-risk) ~80%, stage III ~66%

5-year OS rate: stage II (high-risk) ~88%, stage III ~76%

Interim data expected in late 2025 / early 2026


1. Partnered with Genentech, a member of the Roche Group; 2. Kotani et al., Nature 2023, Nakamura et al., ESMO 2023; 3. André et al., J Clin Onc. 2015.

Functional Vaccine-Induced T Cells are Long-Lived and Detected One Year After Last Vaccination with Autogene Cevumeran¹ in all Evaluable CRC Patients

Kinetics and persistence of T cell responses to vaccine-encoded neoantigens

Elez et. al., Biomarker sub-study results of Phase 2 trial (NCT04486378), ESMO-GI 2024.

Kinetics and durability of ex vivo T cell responses in individual patients (n=12)



Data cut-off March 15, 2024

1. Partnered with Genentech, a member of the Roche Group.

Autogene cevumeran¹ induces T cell responses in all patients

Responses are polyepitopic: against a median of 3 vaccine-encoded neoantigens

Almost all responses were detectable after 8 vaccinations

All 12 patients included in the immunogenicity analysis were disease-free at data cut-off

Autogene Cevumeran¹ Investigated in a Phase 2 Randomized Trial in Combination with Nivolumab in Adjuvant MIUC Patients

Medical need

Standard of care

Neoadjuvant chemotherapy, followed by cystectomy and for eligible patients this is followed by adjuvant treatment with an immune checkpoint inhibitor (ICI).

Unmet medical need

- Adjuvant ICI significantly increases disease-free survival in patients. Despite this, a significant number of patients will relapse in the first two years.²
- The 5-year survival among MIUC patients with distant metastasis has been reported to be about 8%.³

IMCODE004: Phase 2, multi-site, open-label, randomized, controlled trial (NCT06534983)

Inclusion criteria

- Age ≥ 18 years
- Histologically confirmed MIUC or upper urinary tract
- Surgical resection of MIUC of the bladder or upper tract without any adj. chemotherapy or radiotherapy
- Absence of residual disease or metastasis, confirmed by CT or MRI scans
- TNM classification of resected specimen is (y)pT3-4 or (y)pN+ and M0
- ECOG status 0 or 1

Part A: Safety run-in

Autogene cevumeran¹, iv
+
Nivolumab, iv

Part B: Randomized phase

Enrollment
(expected)

n = 362
R 1:1

Autogene cevumeran¹, iv
+
Nivolumab, iv

Q4W for 1 year

Nivolumab, iv
+
Saline solution, iv

Key endpoints:



Primary INV-DFS in PD-L1 ≥ 1
Secondary OS, Safety

Trial currently recruiting

1. Partnered with Genentech, a member of the Roche Group.;2. Bajorin et al., 2021 NEJM; 3. American Cancer Society Cancer Facts and Figures 2024.


Multiple Clinical Trials Demonstrate Execution Across iNeST and FixVac Portfolio

Individualized vaccine: iNeST ¹					FixVac		
Autogene cevumeran (BNT122/RO7198457)					BNT111 ²	BNT113	BNT116
Adjuvant			1L	R/R	R/R	1L	Multiple settings
MIUC Phase 2 + Nivolumab	CRC Phase 2 Monotherapy	PDAC Phase 2 + Atezolizumab	Melanoma Phase 2 + Pembrolizumab	Solid Tumors Phase 1 + Atezolizumab	Melanoma Phase 2 + Cemiplimab	HPV16+ HNSCC Phase 2 + Pembrolizumab	NSCLC Phase 1 & 2 Monotherapy, + Cemiplimab or CTx
Recruitment started	Recruitment ongoing Data presented from epi sub-study at ASCO 2024 and from biomarker sub-study at ESMO-GI 2024 .	Recruitment ongoing Data presented from investigator-initiated Ph 1 trial at ASCO 2022 & AACR 2024 and published. (Rojas et al., Nature 2023)	Enrollment completed Data of prototype version Ph 1 published (Sahin et al., Nature 2017). Analysis of Ph 2 PFS as primary endpoint will be based on events and defined when reporting results.	Enrollment completed Data presented at AACR 2020. Manuscript accepted in Nature Medicine	Enrollment completed Positive topline data announced July 2024 Data presented from Ph 1 at multiple conferences incl. SITC 2021 and published. (Sahin et al., Nature 2020)	Recruitment ongoing Ph 2 data presented at multiple conferences incl. ESMO-IO 2022 Data from safety run-in of Ph 2 trial and Ph1/2 IIT presented at ESMO 2024 .	Recruitment ongoing in Ph 2 in 1L NSCLC ² Ph 1 trial ongoing. Data presented at SITC 2023, AACR 2024 , and SITC 2024 .

1. Partnered with Genentech, a member of the Roche Group; 2. In collaboration with Regeneron.


BNT113 Showed Consistent Immune Responses in Adjuvant and Advanced Disease in Multiple Studies

Vaccine induced T cell responses and consistent clonotype expansion observed in majority of patients
Ottensmeier, et. al. ESMO 2024.



Ex vivo IFN γ ELISpot responses to E6 and/or E7 peptide pools

Vaccine-induced T cell count corresponded with volume of tumor reduction
Saba et. al. ESMO 2024




BNT113 Showed Activity with ORR¹ of 40% in PD-L1+ HPV16+ HNSCC Patients

Results from safety run-in of Phase 2 AHEAD-MERIT in 1L metastatic HNSCC (NCT04534205)

Saba et. al., ESMO 2024

Antitumor activity ²	N=15
Unconfirmed ORR (BICR), %	40.0
CR, n	4
PR, n	2
Unconfirmed DCR (BICR), %	53.3
Unconfirmed ORR (investigator), %	33.3
Unconfirmed DCR (investigator), %	60.0
PFS by BICR	
Median (95% CI), months	3.9 (2.1–10.6)
6-month rate, %	42.3
12-month rate, %	14.1
18-month rate, %	14.1
PFS by investigator	
Median (95% CI), months	6.0 (2.3–10.4)
OS, median (95% CI), months	22.6 (9.8–NE)

Data cut-off: 24 June 2024



1. Assessed per blinded independent central review (BICR); 2. The efficacy analysis set was defined as all patients who received at least one dose of BNT113 (N=15).

BNT113 in Combination with Pembrolizumab as 1L Treatment in Patients with R/R HPV16+ HNSCC Expressing PD-L1

Medical need


Standard of care

Pembrolizumab-based regimens are SoC for patients with PD-L1 CPS≥1, while platinum-based regimens are preferred for patients with PD-L1 CPS<0

Unmet medical need

Up to 25% of patients with early-stage HPV16+ tumors will relapse within two years.¹

5-year survival rates for patients with relapsed advanced HPV16+ tumors is 75%.²



1. Gorphe et al., Radiother Onc 2022 2. Munoz-Bello et. Al, Cell 2024; 3. Harrington et. al., J Clin Oncol. 2023.

BNT116¹-Induced T cell Responses Have Been Observed in NSCLC


Vaccine induced CD4+ and CD8+ T cell responses observed consistently
Öven BB, et. al., presented at AACR 2024. CT051

Patient	Best vaccine response per patient, cell type and target, measured by IFNγ ELISpot post-IVS												BOR
	CLDN6		KK-LC-1		MAGE-A3		MAGE-A4		MAGE-C1		PRAME		Inv.
	CD4 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	
03-016													SD
03-013													PR
03-018													PR

Induced T cell response (ex vivo ELISpot) No response (ex vivo ELISpot) No response (ex vivo ELISpot)

Summary of vaccine responses measured post-IVS by IFNγ ELISpot and response per RECISTv1.1


De novo and vaccine-expanded T cell responses were observed across patients
Atmaca A, et. al., presented at SITC 2024. Poster 1486



1. This trial (NCT05142189) is run under a supply agreement with Regeneron.

Assessing BNT116's Potential in Multiple Combinations and Disease Settings¹

LuCa-MERIT-1: FIH, open-label, Phase 1 trial in NSCLC (NCT05142189)




1. This trial (NCT05142189) is run under a supply agreement with Regeneron.

BNT116 Has Shown Clinical Activity as Single Agent & in Combination with Chemo or anti-PD-1 in Advanced NSCLC in Phase 1 Trial¹

BNT116 monotherapy plus cemiplimab add-on from cycle 3

Deme et al. SITC 2023

Progression after PD-(L)1 therapy, platinum-based chemotherapy, and one other systemic therapy




Combination therapy with BNT116+cemiplimab is active with DCR of 45% in heavily pre-treated lung cancer patients

BNT116 plus docetaxel

Öven et al. AACR 2024

Progression after PD-(L)1 therapy and platinum-based chemotherapy




Combination therapy with BNT116 + docetaxel is active with an ORR of 30% and a DCR of 85% and mPFS of 4.4 months

BNT116 plus cemiplimab

Atmaca et al. SITC 2024

NSCLC with PD-(L)1 TPS ≥50% that progressed after PD-(L)1 therapy as first-line or adjuvant therapy



Combination therapy with BNT116 + cemiplimab is active with an DCR of 80% and a mPFS of 5.5 months


1. This trial (NCT05142189) is run under a supply agreement with Regeneron.

6

Select Targeted Therapies: HER2-ADC BNT323 CLDN6 CART BNT211

Dr. Michael Wenger, MD
VP Clinical Development

Prof. Özlem Türeci, M.D.
CMO and Co-founder




BIONTECH

BNT323/DB-1303¹: A HER2 ADC with a Potentially Differentiated Profile

BNT323/DB-1303¹ is a 3rd generation ADC


- A humanized anti-HER2 IgG1 monoclonal antibody
- A proprietary DNA topoisomerase I inhibitor
- A maleimide tetrapeptide-based cleavable linker



- Cysteine residue
- Linker-payload

Mode of action

Targeted Cytotoxicity



Adapted from Coleman N. et al. npj Precis. Onc. 2023

Preclinical Data


Lin S. et al. Abstract #252. Presented at EORTC-NCI-AACR in 2022 & data on file.

- Superior in vitro **plasma stability** in human plasma
- Rapid **systemic clearance** in monkeys
- Potent **anti-tumor effect in both HER2 positive and HER2 low** tumor models with a wide therapeutic window
- Toxicity studies² in monkeys show **favorable toxicity profile**

Stable linker and fast clearance may contribute to the improved toxicity profile of BNT323/DB-1303¹

1. Partnered with DualityBio; 2. DS-8201 is an in-house produced analog of trastuzumab deruxtecan.

First-in-Human Trial with BNT323/DB-1303¹ in Patients with Advanced HER2-Expressing Solid Tumors



BNT323/DB-1303¹ Data Facilitates a Potential Path to Registration in HER2-Expressing Endometrial Cancer

Phase 1/2a FIH study (NCT05150691): Clinical Efficacy

Moore K. et al. Presented at ESGO 2023. Abstract # 430


- HER2 tumor expression of IHC 1, 2 and 3+: 31%, 41% and 25%, respectively. Clinical response observed across HER2-expression levels, including IHC 1+
- Patients received median 2 lines of prior treatment. ~60% of patients had prior IO, ~38% prior anti-HER2 antibody
- Data cutoff: May 8, 2023

Response ^a	Dose Escalation		Dose Expansion	Total (n=17) ^b
	7 mg/kg (n=4) ^b	8 mg/kg (n=4) ^b	8 mg/kg (n=9) ^b	
Unconfirmed ORR, n (%)	2 (50)	4 (100)	4 (44)	10 (59)
Confirmed ORR, n (%)	1 (25)	3 (75)	0	4 (24)
Pending confirmation ORR, n (%)	1 (25)	1 (25)	4 (44)	6 (35)
Unconfirmed DCR, n (%)	4 (100)	4 (100)	8 (89)	16 (94)

^a By investigator. ^b Response-evaluable subjects, which includes subjects with ≥1 postbaseline overall response.

Benchmark comparator data for 2L+ HER2+ Endometrial Cancer

Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
Endometrial	T-DXd	57.5%	11.1 mo	26.0 mo	DESTINY-PanTumor02 ²




1. Partnered with DualityBio; 2. Meric-Bernstam F. et al. J Clin Oncol 2024.

Phase 3 Study of BNT323/DB-1303¹ vs Chemotherapy in 2L+ HER2-expressing Endometrial Cancer

BNT323-01: (NCT06340568)

Key inclusion criteria

- Recurrent, metastatic endometrial cancer (including HER2 1+, 2+, or 3+ score on IHC by central testing)
- At least 1 prior line of platinum-based therapy (in any setting) and prior ICI (in any setting), up to three lines of prior therapy (excluding endocrine therapies)
- Measurable disease per RECIST v1.1
- ECOG PS 0 or 1




**Key endpoints**
Primary endpoints: PFS (BICR assessed)

Benchmark comparator data for 2L+ Endometrial Cancer


Indication	Benchmark regimen	ORR	mPFS	mOS	Benchmark Study
Endometrial	Single-agent chemo	14.7%	3.8 mo	11.4 mo	KEYNOTE-775 ²

1. Partnered with DualityBio; 2. Makker V. et al. NEJM 2022.


Claudin-6 (CLDN6) is a Carcinoembryonic Cell Surface Antigen




- Claudins are tight junction-associated tetraspanins with druggable extracellular loops
- Expressed exquisitely during organogenesis and not in healthy adult tissues
- Highly expressed in various cancer types with correlation to disease progression
- Cancer stem cell marker



Human Tissue Panel



CLDN6 is Expressed in High Medical Need Cancers Including Lung Cancer



Indication	CLDN6 ⁺	CLDN6 ^{high}
Testicular Cancer*	93 %	90-93 %
Ovarian Cancer*	56 %	25-30 %
Uterine Cancer*	23 %	10-15 %
Lung Cancer**	11 %	2-5 %
Gastric Cancer***	9 %	2-5 %




CLDN6^{high} = 50% of tumor cells expressing ≥2+ CLDN6 protein (IHC)

Reinhard et al., Science 2020

CLDN6 IHC staining of a TMA with 355 NSCLC

	tested	CLDN6 ⁺
Squamous CA	120	0
AdenoCA	195	20 (10%)
Large cell CA	40	3 (7.5%)
Total	355	23 (6.5%)

- No correlation with smoking history, Ki67+ status, tumor stage, WHO performance stage
- Negatively correlated with prognosis
- Correlated with TFF1+ status




Micke et al.,
Int. J. Cancer 2014



BNT211: a CLDN6 CAR-T-Cell Therapy + CLDN6-Encoding CARVac that Enhances Expansion and Persistence of the Infused CAR-T Cells

Potent 2nd generation CAR with high sensitivity and specificity

Reinhard K, et al. *Science* 2020, 367:446–453



Combined with CARVac (CAR-T cell amplifying RNA vaccine) to target APCs, Reinhard K, et al. *Science* 2020, 367:446–453; Kranz LM, et al. *Nature* 2016; 534:396–401



BNT211 as Monotherapy or in Combination with Ribonucleic Acid Lipoplexes (RNA-LPX) in Patients with CLDN6-Positive Advanced Solid Tumors

Phase 1, FIH, open-label, dose escalation study with expansion cohort to evaluate safety and efficacy of BNT211 with/without RNA-LPX in patients with CLDN6+ R/R solid tumors (NCT04503278)

Key inclusion criteria


- $\geq 50\%$ tumor cells with CLDN 6 IHC 2+/3+ CLDN6 positivity (immunohistochemistry)
- Measurable disease per RECIST v1.1 or elevated tumor marker
- ECOG PS 0–1

ESMO 2022

Part A: Manual product (n=22; completed)¹

Monotherapy

Combination*




Published in:
Mackensen et al., Nature Medicine, 2023

ESMO 2023

Part B: Automated product (n=78; ongoing)²

Monotherapy

Combination



*aThree patients were treated at an optional de-escalation dose (DL 1.5=5x10⁷ cells) to further evaluate clinical safety and efficacy.



Key endpoints

Primary:

Safety & tolerability, MTD, RP2D


Secondary:

ORR, DCR, DOR

1. Mackensen A, et al. Nature Med 2023;29:2844–2853; 2. Haanen JBAG, et al. Ann Oncol 2023;34 (suppl_2):S1281–S1282.

BNT211-01: Overall Response Rate – Testicular Cancer

Overall ORR was 24%; at DL2 and DL3 ORR was 41.7%.
Two patients had a surgical complete response that lasted for over a year. Haanen et. al., ESMO 2024



Response ^a	Total (N=27) ^b
Evaluable patients, n	25
ORR, n (%)	6 (24.0)
95% CI (%)	8.6–42.3
DCR, n (%)	14 (56.0)
95% CI (%)	32.0–71.3


Response ^a	DL $\geq$ 2 +100% LD $\pm$ CARVac (N=14) ^{b,c}
Evaluable patients, n	12
ORR, n (%)	5 (41.7)
95% CI (%)	12.8–64.9
DCR, n (%)	9 (75.0)
95% CI (%)	35.1–87.2

Data cut-off: May 16, 2024.

a. Includes tumor marker responses; b. Excludes patients who received an out-of-specification product; c. DL2=1 $\times$ 10⁸; DL3=2–5 $\times$ 10⁸ CAR T cells.

BNT211-01: Overall Response Rate – Ovarian Cancer

In the 24 evaluable patients across all dose levels, ORR was 33.3% and DCR was 75% - the same parameters when considered for Dose Level 2 and above were 58.3% and 83.3% respectively.
Haanen et. al., ESMO 2024




a. Includes tumor marker responses; b. Excludes patients who received an out-of-specification product; c. DL2=1×10⁸; DL3=2–5×10⁸ CAR T cells.


Data cut-off: May 16, 2024.

Best Overall Response to CLDN6 CAR T+ CARVac in a Patient with NSCLC¹

Best overall response was PR



- Patient with AGA-neg NSCLC, CLDN6+ (50% 2+/3+, 80% any positivity), IO-experienced,
- 2 previous treatment lines, former smoker
- Received CAR T + 5x CARVac




Target lesion size			
Screening	ACT	ACT + 1 Mo	ACT + 3 Mo
18 mm	53 mm	28 mm	12 mm
	+194%	-47%	-77%
		PR	PR

1. Data on file. Presented by U. Sahin at Lung Cancer Summit, NY, 2024



CARVac Improves CAR T Persistence

Adding CARVac limits the decline and induces a plateau of CAR-T cells with robust and ongoing detection in patients¹ who received DL2+CARVac. Haanen et. al., ESMO 2024

DL2 (1x10⁸) CAR T alone



DL2 (1x10⁸) CAR T + CARVac




Data cut-off: May 16, 2024.

1. At day 50, the proportion of patients with measurable CAR T > than the lower limit of quantification is 6 of 8 for CAR T alone and 12 of 12 for CAR T plus CARVac. At Day 90, 1/7 had detectable CAR T in the CAR T alone group vs 6/8 in the CAR T plus CARVac group.

mOS of 7.7 Months in Patients with R/R Testicular Germ Cell Tumors After Initiating Palliative Chemotherapy

Real-world evidence study: Results objective 1
Feldman, D. et al. ASCO 2024.

OS among patients with R/R testicular GCT receiving palliative chemotherapy exposure with sufficient follow-up time (N=80)



Time from the index date	0 month	6 months	12 months	24 months
Prior HDCT ± CDCT				
Pts at risk, N	49	29	8	2
Cumulative deaths, N	0	20	41	45
Survival probability, %	100.0	59.2	16.3	6.3
Prior CDCT only				
Pts at risk, N	31	22	12	6
Cumulative deaths, N	0	9	19	24
Survival probability, %	100.0	71.0	38.7	21.5

OS was assessed among 80 patients with R/R testicular GCT who had at least 12 months of follow-up time, which are a subgroup of patients identified for Objective 1 (N = 97).

BNT211 Pivotal Trial in Patients with R/R Testicular Germ Cell Tumors


BNT211-02 open-label, randomized Phase 2 study to evaluate safety and efficacy of BNT211 in adult patients with testicular or extragonadal germ cell tumors

Key inclusion criteria

- RECIST 1.1 or serum tumor markers
- Prior high dose chemo + autologous SCT or conventional dose chemo as salvage therapy
- $\geq 25\%$ of tumor cells expressing CLDN6
- ECOG performance status 0-1
- Adequate organ function

Safety lead-in part: 3-arm, randomized (1:1:1)

Main part: single arm




Key endpoints

	Safety lead-in	Main part
Primary	Safety & tolerability, TEAEs, AESIs, serious/fatal TEAEs	ORR per RECIST1.1, reduction of serum tumor marker
Secondary	Efficacy (ORR, DCR, DOR), PK	PFS, OS, DOR, DCR, safety, PK, pharmacodynamics, immunogenicity

7

Path to Value Creation

Ryan Richardson,
Chief Strategy Officer




BIONTECH

Progress in the Last Twelve Months Demonstrates the Strength of our Model and our Strategy

		2023	→	2024
	COVID-19	Maintained leading market share (>50%)		
	Oncology Portfolio	7 Phase 2/3 trial starts >67% year-on-year increase in average quarterly patient enrollment in trials		
	Infectious Disease Vaccine Portfolio	Three Phase 1 trial starts		
	Corporate Development	Acquisitions of InstaDeep and Biotheus announced Six in-licensed molecules		
	Cash Balance	Grew cash balance from Q3 2023 to Q3 2024 (€17.0B to €17.8B ¹)		

1. Consists of cash and cash equivalents of €9,624.6 million, current security investments of €7,078 million and non-current security investments of €1,137.2 million, as of September 30, 2024, and does not include announced Biotheus acquisition considerations.

Our Capital Allocation Strategy Going Forward Will Continue to Focus on Value Creation



Outlook for 2025

- Strategically invest** behind late-stage programs with transformational potential
- Active **portfolio management** to create additional P&L headroom for pivotal trial investment
- Expect to continue to benefit from **interest income** potential from strategic cash reserve

Expected Potential Value Creating Milestones and Trials

2024 - 2025+			Ongoing and Planned Trials with Anticipated Data Disclosures Beyond 2025		
 BNT327/PM8002² 1L TNBC Phase 2 data	BNT327/PM8002² 1L SCLC Phase 2 data	BNT327/PM8002² 1L ES-SCLC and 2L SCLC Phase 2 DO data	BNT323/DB-1303³ HR+ HER2 low BC Phase 3	Autogene cevumeran (BNT122/RO7198457)⁴ adj. PDAC Phase 2	Autogene cevumeran (BNT122/RO7198457)⁴ adj. PD-L1+ MIUC Phase 2
BNT327/PM8002² 1L and 2L TNBC Phase 2 DO data	BNT323/DB-1303³ 2L+ HER2 EC Phase 2 data	Autogene cevumeran (BNT122/RO7198457)⁴ ctDNA adj. CRC Phase 2 topline data	BNT327/PM8002² 1L SCLC Phase 3	BNT327/PM8002² 1L NSCLC Phase 3	BNT327/PM8002² 1L TNBC Phase 3
BNT111⁵ 2L+ melanoma Phase 2 data		BNT323/DB-1303³ 2L+ HER2 EC Regulatory submission	BNT113 HPV16+ PD-L1+ HNSCC Phase 2	BNT116⁶ PD-1L > 50% 1L NSCLC Phase 2	BNT316⁵ 2L NSCLC Phase 3

■ Data update
■ Regulatory event

Catalyst-rich upcoming period for mid- to late-stage pipeline to support company vision to achieve a diversified, cashflow-generating multi-product oncology portfolio by 2030

Partnered with: 1. Pfizer; 2. Biotheus; 3. DualityBio; 4. Genentech, member of Roche Group; 5. OncoC4; 6. in collaboration with Regeneron; DO = Dose Optimization.

THANK
YOU

Contact us at *investors@biontech.de*

Abbreviations (1)

<i>n</i> L	<i>n</i> th line	CRC	Colorectal cancer	FIH	First in human
AACR	American Association for Cancer Research	CRS	Cytokine release syndrome	Flu	Fludarabine
ACT	Adoptic cell transfer	CRT	Chemoradiation therapy	FPD	First patient dosed
ADC	Antibody-drug conjugate	CT	Computer tomography	GBM	Glioblastoma
adj.	Adjuvant	CTCAE	Common terminology criteria for adverse events	GC/GEJ	Gastric/Gastro-esophageal junction cancer
AE	Adverse event	ctDNA	Circulating tumor DNA	GCT	Germ cell tumor
AGA	Actionable oncogenic alteration	CTFI	Chemotherapy-free interval	GEJ	Gasto-esophageal junction
AI	Artificial intelligence	CTLA-4	Cytotoxic T-lymphocyte-associated protein 4	HCC	Hepatocellular carcinoma
ALK	Anaplastic large-cell lymphoma kinase	CTx	Chemotherapy	HDCT	High dose chemotherapy
APC	Antigen presenting cell	CXCL	Chemokine (C-X-C motif) ligand	HER2 (or 3)	Human epidermal growth factor receptor 2 (or 3)
ASCO	American Society of Clinical Oncology	Cy	Cyclophosphamide	HLA	Human leukocyte antigen
(m)BC	(metastatic) Breast cancer	DAR	Drug-antibody ratio	HLH	Hemophagocytic lymphohistiocytosis
BIRC	Blinded independent central review	DC	Dendritic cell	HNSCC	Head and neck squamous cell carcinoma
BL	Baseline	DCR	Disease control rate	HPV	Human papilloma virus
BOR	Best overall response	DDC	Duration of disease control	HR	Hazard ratio
BTC	Biliary tract cancer	DFS	Disease-free survival	HR	Hormone receptor
CAR	Chimeric antigen receptor	DL	Dose level	ICANS	Immune effector cell-associated neurotoxicity syndrome
CARVac	CAR T-cell amplifying RNA vaccine	DLT	Dose limiting toxicity	ICI	Immune checkpoint inhibitor
<i>CnDn</i>	Cycle <i>n</i> day <i>n</i>	dMMR	Deficient DNA mismatch repair	IDMC	Independent Data Monitoring Committee
CD	Cluster of differentiation	(m)DOR	Duration of response	IEC-HS	Immune effector cell-associated HLH-like syndrome
CDCT	Conventional dose chemotherapy	EC	Endometrial cancer	IFN	Interferon
cGMP	Current Good Manufacturing Practice	ECOG (PS)	Eastern Cooperative Oncology Group (performance status)	IgG	Immunoglobulin G
CI	Confidence interval	E2E	End to end	IHC	Immunohistochemistry
CICON	International Cancer Immunotherapy Conference	EGFR	Epidermal growth factor receptor	IIT	Investigator initiated trial
CLDN6	Claudin 6	ELISpot	Enzyme Linked Immuno Spot Assay	IL-x	Interleukin x
CMC	Chemistry, manufacturing and control	EORTC	European Organisation for Research and Treatment of Cancer	IND	Investigational new drug
COGS	Cost of goods sold	ER	Estrogen receptor	iNeST	Individualized NeoAntigen-Specific Therapy
CPD	Confirmed progression	ESMO	European Society for Medical Oncology	INV-	Investigator assessed
CPI	Checkpoint inhibitor	ESMO GI	European Society for Medical Oncology Gastrointestinal	IO	Immuno-oncology
CPS	Combined positive score	Fab	Fragment antigen binding	IPO	Initial public offering
CR	Complete response	FDA	U.S. Food and Drug Association	IQR	Interquartile range

Abbreviations (2)

irAE	Immune-related adverse event	NSCLC	Non-small cell lung cancer	SITC	Society of Immunotherapy of Cancer
ISH	in-situ hybridization	NY-ESO-1	New York esophageal squamous cell carcinoma-1	S&M	Sales and marketing
ITT	Intention to treat	OPEX	Operational expenditures	SoC	Standard of care
iv	Intravenously	(c)ORR	(Confirmed) objective response rate	SoD	Sum of diameters
IvS	<i>in vitro</i> stimulation	OS	Overall survival	TAA	Tumor-associated antigen
KK-LC-1	Kita-Kyushu lung cancer antigen 1	PBMC	Peripheral blood mononuclear cell	TAP	Transporter associated with antigen processing
LCM	Life cycle management	PD	Progressive disease	TC	Testicular cancer
LLOQ	Lower limit of quantification	PDAC	Pancreatic ductal adenocarcinoma	TCGA	The Cancer Genome Atlas
LD	Lymphodepletion	PD-(L)1	Programmed cell death protein (ligand) 1	TCR	T-cell receptor
LPX	Lipoplex	PFS	Progression-free survival	TEA	Tissue engineering acoustophoretic
m	Median	PK	Pharmacokinetics	TE(S)AE	Treatment-emergent (serious) adverse event
mAB	Monoclonal antibody	PoC	Proof of concept	TKI	Tyrosine kinase inhibitor
MAGE-A3	Melanoma antigen A3	PoT	Proof of technology	TLR	Toll-like receptor
MHC	Major histocompatibility complex	PR	Partial response	TME	Tumor microenvironment
MIUC	Muscle-invasive urothelial carcinoma	PR	Progesterone receptor	TNBC	Triple-negative breast cancer
MMR	Mismatch repair	PRAME	Preferentially expressed antigen in melanoma	TNF	Tumor necrosis factor
MΦ	Macrophage	PROC	Platinum-resistant ovarian cancer	TNM	Classification of malignant tumors (tumor-nodus-metastasis)
MoA	Mechanism of Action	PSOC	Platinum-sensitive ovarian cancer	TPS	Tumor proportion score
MPM	Malignant pleural mesothelioma	QxW	Every x week(s)	TRAE	Treatment-related adverse event
MRI	Magnetic resonance imaging	R	Randomized	Treg	Regulatory T cell
mRNA	Messenger ribonucleic acid	(ncc/cc)RCC	(Non-clear cell/clear cell) renal cell carcinoma	TRON	Helmholtz Institute for Translational Oncology
MSI-H (L)	High(low)-frequency microsatellite instability	R&D	Research and development	TROP2	Trophoblast cell-surface antigen 2
MSKCC	Memorial Sloan Kettering Cancer Center	RECIST	Response Evaluation Criteria in Solid Tumors	TTF	Time to treatment failure
MSS	Microsatellite stability	RFS	Recurrence-free survival	TTP	Time to progression
MTD	Maximum tolerated dose	RP2D	Recommended phase 2 dose	TTR	Time to response
NCI PRO-CTCAE	National Cancer Institute Patient Reported Outcome Common Terminology Criteria for Adverse Events	R/R	Relapsed/refractory	UC	Urothelial cancer
NEN	Neuroendocrine neoplasm	RT-qPCR	Real-time quantitative polymerase chain reaction	UICC	Union for International Cancer Control
NF-κB	Nuclear factor kappa B	SAE	Severe adverse event	UPD	Unconfirmed progression
NGS	Next generation sequencing	(E/LS)SCLC	(Extensive/low stage) small cell lung cancer	VEGF(R)	Vascular endothelial growth factor (receptor)
NR	Not reached	scFv	Single-chain variable fragment	VHH	Heavy chain variable
		SD	Stable disease	WT	Wild type